BACKGROUND: The impact of adherence to clinical practice guidelines (CPGs) for loco-regional treatment (i.e. surgery and radiotherapy) and chemotherapy on local disease control and survival in sarcoma patients was investigated in a European study conducted in an Italian region (Veneto). PATIENTS AND METHODS: The completeness of the adherence to the Italian CPGs for sarcomas treatment was assessed by comparing the patient's charts and the CPGs. Propensity score-adjusted multivariate survival analysis was used to assess the impact of CPGs adherence on patient clinical outcomes. RESULTS: A total of 151 patients were included. Adherence to CPGs for loco-regional therapy and chemotherapy was observed in 106 out of 147 (70.2%) and 129 out of 139 (85.4%) patients, respectively. Non-adherence to CPGs for loco-regional treatment was independently associated with AJCC stage III disease [odds ratio (OR) 1.77, P = 0.011] and tumor-positive excision margin (OR 3.55, P = 0.003). Patients not treated according to the CPGs were at a higher risk of local recurrence [hazard ratio (HR) 5.4, P < 0.001] and had a shorter sarcoma-specific survival (HR 4.05, P < 0.001), independently of tumor stage. CONCLUSIONS: Incomplete adherence to CPGs for loco-regional treatment of sarcomas was associated with worse prognosis in patients with non-metastatic tumors.
BACKGROUND: The impact of adherence to clinical practice guidelines (CPGs) for loco-regional treatment (i.e. surgery and radiotherapy) and chemotherapy on local disease control and survival in sarcomapatients was investigated in a European study conducted in an Italian region (Veneto). PATIENTS AND METHODS: The completeness of the adherence to the Italian CPGs for sarcomas treatment was assessed by comparing the patient's charts and the CPGs. Propensity score-adjusted multivariate survival analysis was used to assess the impact of CPGs adherence on patient clinical outcomes. RESULTS: A total of 151 patients were included. Adherence to CPGs for loco-regional therapy and chemotherapy was observed in 106 out of 147 (70.2%) and 129 out of 139 (85.4%) patients, respectively. Non-adherence to CPGs for loco-regional treatment was independently associated with AJCC stage III disease [odds ratio (OR) 1.77, P = 0.011] and tumor-positive excision margin (OR 3.55, P = 0.003). Patients not treated according to the CPGs were at a higher risk of local recurrence [hazard ratio (HR) 5.4, P < 0.001] and had a shorter sarcoma-specific survival (HR 4.05, P < 0.001), independently of tumor stage. CONCLUSIONS: Incomplete adherence to CPGs for loco-regional treatment of sarcomas was associated with worse prognosis in patients with non-metastatic tumors.
Entities:
Keywords:
clinical practice guidelines; prognosis; sarcomas
Authors: Luca G Campana; Giuseppe Bianchi; Simone Mocellin; Sara Valpione; Laura Campanacci; Antonella Brunello; Davide Donati; Elisabetta Sieni; Carlo R Rossi Journal: World J Surg Date: 2014-04 Impact factor: 3.352
Authors: Emily Z Keung; Yi-Ju Chiang; Janice N Cormier; Keila E Torres; Kelly K Hunt; Barry W Feig; Christina L Roland Journal: Cancer Date: 2018-10-14 Impact factor: 6.860
Authors: S Mathoulin-Pélissier; C Chevreau; C Bellera; E Bauvin; M Savès; P Grosclaude; S Albert; J Goddard; S Le Guellec; M Delannes; B N Bui; J Mendiboure; E Stoeckle; J M Coindre; G Kantor; M Kind; A Cowppli-Bony; S Hoppe; A Italiano Journal: Ann Oncol Date: 2013-11-26 Impact factor: 32.976
Authors: Alessandro Coran; Paolo Ortolan; Shady Attar; Enrico Alberioli; Egle Perissinotto; Anna Lisa Tosi; Maria Cristina Montesco; Carlo Riccardo Rossi; Saveria Tropea; Marco Rastrelli; Roberto Stramare Journal: In Vivo Date: 2017 May-Jun Impact factor: 2.155
Authors: Mark A Kashtan; Thejus T Jayakrishnan; Rahul Rajeev; John C Charlson; Fabian Johnston; T Clark Gamblin; Kiran K Turaga Journal: Int J Clin Oncol Date: 2015-12-08 Impact factor: 3.402